Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT07135453
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Pneumococcal Disease
  • Vaccine

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Pneumococcal Vaccine — BIOLOGICAL
    PCV

Study Details

The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria. We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.

Key Dates

Start date
May 31, 2026
Status verified
May 2026
Primary completion
Mar 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
70 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: PCV20
    Will receive PCV20
  • Experimental: PCV21
    Will receive PCV21

Primary Outcome Measure

Serogroup 33 antibodies [ Time Frame: 4 weeks post-vaccination ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294
LaFon, MD
[email protected]
2059343411
David C LaFon, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

By research site
University of Alabama at Birmingham· Birmingham, AL

Related Studies